SCHEDULE 13G: Ikarian Capital Discloses 6.8% Passive Stake in Avenue Therapeutics
Ownership Disclosure
Ikarian Capital, LLC and Neil Shahrestani have jointly disclosed a passive 6.8% beneficial ownership stake in Avenue Therapeutics, Inc., holding 140,000 shares of common stock.
Summary
- Ikarian Capital, LLC and Neil Shahrestani (collectively, the "Reporting Persons") have filed a Schedule 13G, indicating beneficial ownership of 140,000 shares of Avenue Therapeutics, Inc. common stock.
- This ownership represents 6.8% of Avenue Therapeutics' outstanding common stock.
- The percentage is calculated based on 2,053,923 shares of common stock outstanding as of December 3, 2024, as disclosed in Avenue Therapeutics' Form S-3 filed on December 4, 2024.
- Ikarian Capital, a Delaware limited liability company, is an investment adviser and serves as investment manager to Ikarian Healthcare Master Fund, L.P. and sub-adviser to certain separately managed accounts, which are the record owners of the securities.
- Neil Shahrestani indirectly controls Ikarian Capital and is therefore deemed to indirectly beneficially own the securities.
- The Reporting Persons certify that the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of Avenue Therapeutics, Inc.
Sentiment
Score: 6
Explanation: The sentiment is slightly positive as it indicates an institutional investor has taken a significant stake in the company, which can be viewed as a vote of confidence, albeit a passive one.
Positives
- The disclosure of a significant passive stake by an institutional investor like Ikarian Capital may signal confidence in Avenue Therapeutics, Inc. from a notable investment firm.
Risks
- The Reporting Persons disclaim that the filing of this statement or anything herein shall be construed as an admission that they are acting as a partnership, limited partnership, syndicate, or other group for the purpose of acquiring, holding, or disposing of securities of the issuer or otherwise with respect to the issuer or any securities of the issuer.
Future Outlook
The document does not contain any forward-looking statements or guidance from Avenue Therapeutics, Inc. or the Reporting Persons regarding the issuer's future performance or strategic direction.
Industry Context
This filing indicates a significant passive investment by a specialized healthcare investment firm in Avenue Therapeutics, Inc., a company in the pharmaceutical or biotechnology sector. Such disclosures are common in the investment landscape, reflecting institutional interest in specific companies within the industry.
Stakeholder Impact
- Shareholders: The disclosure of a new significant shareholder provides transparency regarding the company's ownership structure and may influence investor perception and trading activity.
Key Dates
| Date | Description |
|---|---|
| 2024-12-03 | Date as of which 2,053,923 shares of Common Stock of Avenue Therapeutics, Inc. were outstanding, as disclosed in the Issuer's Form S-3. |
| 2024-12-04 | Date of Avenue Therapeutics, Inc.'s Form S-3 filing with the U.S. Securities and Exchange Commission (SEC). |
| 2024-12-31 | Date of event which requires the filing of this Schedule 13G statement. |
| 2025-02-14 | Date of signature for Ikarian Capital, LLC and Neil Shahrestani on the Schedule 13G filing. |
| 2025-02-14 | Effective date of the Joint Filing Agreement between Ikarian Capital, LLC and Neil Shahrestani. |
Keywords
Avenue Therapeutics, Ikarian Capital, Neil Shahrestani, Schedule 13G, Beneficial Ownership, Common Stock, Investment Adviser, Passive Investment, SEC Filing, Healthcare Investment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.